Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MIT and India to Create Health Science and Technology Institute (India)

This article was originally published in PharmAsia News

Executive Summary

MIT and the government of India's Department of Biotechnology has launched a partnership that will result in the creation of a new Translational Health Science and Technology Institute (THSTI) in India. This new institute, which will be modeled after the Harvard-MIT Division of Health Sciences and Technology (HST), will include faculty from multiple disciplines and professions, offer degrees through multidisciplinary programs, and develop strong ties with other institutions. Funded by the Indian government, the Indian HST will be a multidisciplinary, multiprofessional research and training center that is highly interconnected with regional centers of excellence. The institute will increase India's capacity for translating scientific and technological advancements into medical innovations that have the potential to improve healthcare both in India and around the world. To foster a culture of innovation in THSTI, HST will help recruit and train new THSTI faculty members. Each year starting in September 2008 and continuing until 2011, four recruited THSTI faculty fellows will join the HST faculty. These faculty fellows will train at HST for two years. During their stay they will develop translational research programs, design courses and curricula for THSTI, and develop close relationships with HST faculty and students. (Click here for more

You may also be interested in...



Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

People On The Move: Appointments At Stada, PGEU, And UK Health Claims Committee

Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel